» Articles » PMID: 18363832

A Role for the Transcription Factor HEY1 in Glioblastoma

Abstract

Abstract Glioblastoma multiforme (GBM), the highest-grade glioma, is the most frequent tumour of the brain with a very poor prognosis and limited therapeutic options. Although little is known about the molecular mechanisms that underlie glioblastoma formation, a number of signal transduction routes, such as the Notch and Ras signalling pathways, seem to play an important role in the formation of GBM. In the present study, we show by in situ hybridization on primary tumour material that the transcription factor HEY1, a target of the Notch signalling pathway, is specifically up-regulated in glioma and that expression of HEY1 in GBM correlates with tumour-grade and survival. In addition, we show by chromatin immunoprecipitations, luciferase assays and Northern blot experiments that HEY1 is a bona fide target of the E2F family of transcription factors, connecting the Ras and Notch signalling pathways. Finally, we show that ectopic expression of HEY1 induces cell proliferation in neural stem cells, while depletion of HEY1 by RNA interference reduces proliferation of glioblastoma cells in tissue culture. Together, these data imply a role for HEY1 in the progression of GBM, and therefore we propose that HEY1 may be a therapeutic target for glioblastoma patients. Moreover, HEY1 may represent a molecular marker to distinguish GBM patients with a longer survival prognosis from those at high risk.

Citing Articles

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A Mol Cancer. 2025; 24(1):58.

PMID: 40011944 PMC: 11863469. DOI: 10.1186/s12943-025-02267-0.


Mapping the developmental trajectory of human astrocytes reveals divergence in glioblastoma.

Sojka C, Wang H, Bhatia T, Li Y, Chopra P, Sing A Nat Cell Biol. 2025; 27(2):347-359.

PMID: 39779941 DOI: 10.1038/s41556-024-01583-9.


Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.

Norollahi S, Yousefi B, Nejatifar F, Yousefzadeh-Chabok S, Rashidy-Pour A, Samadani A J Egypt Natl Canc Inst. 2024; 36(1):33.

PMID: 39465481 DOI: 10.1186/s43046-024-00240-4.


Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets.

Cortes Ballen A, Amosu M, Ravinder S, Chan J, Derin E, Slika H Cells. 2024; 13(18.

PMID: 39329757 PMC: 11430559. DOI: 10.3390/cells13181574.


Gene regulatory network topology governs resistance and treatment escape in glioma stem-like cells.

Park J, Hothi P, de Lomana A, Pan M, Calder R, Turkarslan S Sci Adv. 2024; 10(23):eadj7706.

PMID: 38848360 PMC: 11160475. DOI: 10.1126/sciadv.adj7706.


References
1.
Yoon K, Gaiano N . Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci. 2005; 8(6):709-15. DOI: 10.1038/nn1475. View

2.
Nakagawa O, McFADDEN D, Nakagawa M, Yanagisawa H, Hu T, Srivastava D . Members of the HRT family of basic helix-loop-helix proteins act as transcriptional repressors downstream of Notch signaling. Proc Natl Acad Sci U S A. 2000; 97(25):13655-60. PMC: 17631. DOI: 10.1073/pnas.250485597. View

3.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

4.
Iso T, Kedes L, Hamamori Y . HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol. 2003; 194(3):237-55. DOI: 10.1002/jcp.10208. View

5.
Callaghan D, Dong L, Callaghan S, Hou Y, Dagnino L, Slack R . Neural precursor cells differentiating in the absence of Rb exhibit delayed terminal mitosis and deregulated E2F 1 and 3 activity. Dev Biol. 1999; 207(2):257-70. DOI: 10.1006/dbio.1998.9162. View